Avelos Therapeutics is a Seoul-based clinical-stage oncology biotech founded in 2021 that designs small-molecule drugs for 'undruggable' cancer targets using synthetic lethality, DNA damage response (DDR), and cell-cycle biology. Its lead program, AD1208, is a first-in-class oral MASTL kinase inhibitor now in a Phase 1/2a solid-tumor trial. Backed by KRW 30 billion (~$21.7M) across seed, Series A, and a 2024 Series B, the roughly nine-person team is building a biomarker-driven pipeline of four anti-cancer candidates aimed at a future KOSDAQ listing.
Soongyu Choi is the co-CEO and co-founder of Avelos Therapeutics, a Seoul-based clinical-stage precision oncology company chasing first-in-class small molecules in synthetic lethality, DNA damage response, and cell cycle control. A Harvard-trained chemist who spent a decade at PTC Therapeutics and led R&D at Yuhan and Hana Pharm, he co-founded Avelos in 2021 and was elevated from CTO to co-CEO in January 2024. His flagship program, AD1208, is a first-in-class MASTL kinase inhibitor he frames as a precise strike on cancers that have stopped responding to standard therapy.